Arthritis is an indication for drug development with over 470 pipeline drugs currently active. According to GlobalData, preregistered drugs for Arthritis have a 91.3% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Arthritis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Arthritis overview
Inflammation in joints is referred to as arthritis. Rheumatoid arthritis and Osteoarthritis are the common arthritis. Psoriatic arthritis, gout, lupus, spondylitis, cervical spondylosis are less common cases of arthritis. Causes are these are inflammatory autoimmune disorders triggered by external factors. Joint pains in more than 5 fingers or joints, morning sickness, wearing and tearing, pain, inflammation or redness. RA factor, ESR are common diagnostic approaches done. DMARDS, steroids, and analgesics are primary treatments and non-pharmacological therapy like physiotherapy, hot and cold packs.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Arthritis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
